Afalaza tablets, no. 100

The drug Afalaza is indicated for use in adults.

• benign prostatic hyperplasia;

• dysuric disorders (as part of complex therapy): frequent urge to urinate, difficulty urinating, pain and discomfort in the perineum, accompanying benign prostatic hyperplasia.

The drug is taken orally, 2 tab. 2 times / day, in the evening and in the morning (keep in the mouth until completely dissolved - outside the meal). The risk is not intended for dividing the tablet into parts.

For dysuric disorders, the drug is recommended to be taken within 16 weeks.

On the recommendation of a doctor, with severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, taking the drug up to 4 times / day is indicated.

To prevent the growth of the prostate gland in patients with BPH and reduce the risk of disease progression, the drug is recommended to be taken 2 times / day, in the evening and in the morning, for 12 months.

Lozenges from white to almost white, flat-cylindrical shape, with a score and a bevel; the flat side with a line has the inscription MATERIA MEDICA, the other flat side has the inscription AFALAZA.

1 tab.

antibodies to endothelial NO-synthase affinity purified 0.006 g * antibodies to prostate-specific antigen affinity purified 0.006 g *

* applied to lactose in the form of a mixture of three active aqueous-alcoholic dilutions of the substance, diluted 10012, 10030, 100200 times, respectively.

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

• age under 18;

• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

• increased individual sensitivity to the components of the drug.

pharmachologic effect

It has been experimentally and clinically shown that affinity purified antibodies to PSA modify the functional activity of endogenous PSA, altered in benign prostatic hyperplasia, which is accompanied by an increase in the regulatory effect of this antigen on functional and metabolic processes in the prostate tissue, and have a pronounced anti-inflammatory and decongestant effect.

Affinity purified antibodies to endothelial NO-synthase increase the blood flow rate, incl. in the vessels of the penis and prostate gland; has a protective effect against the endothelium (helps to reduce vascular reactivity, reduce vascular spasm and improve peripheral microcirculation).

The combined use of the components in the complex preparation Afalaza is accompanied by a synergistic effect: antibodies to endothelial NO-synthase, due to the endothelioprotective effect and improved vascularization, enhance the antiproliferative and anti-inflammatory activity of antibodies to PSA. The synergistic effect is probably also due to nonspecific mechanisms for enhancing intracellular signal transduction by dilutions of antibodies to endothelial NO synthase.

In patients with BPH, when used for 12 months, the drug helps to reduce the volume of the prostate gland, improve urodynamic parameters (decrease in residual urine volume, increase the maximum urine velocity), and significantly reduce the severity of dysuric disorders without affecting the PSA level.

The drug helps to improve the quality of life of patients with BPH.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active components of Afalaza in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Side effect

Possible reactions of increased individual sensitivity to the components of the drug.

Application during pregnancy and lactation

Afalaza is not intended for use in women.

Application in children

The use of the drug under the age of 18 is contraindicated.

special instructions

The drug contains lactose monohydrate, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or congenital lactase deficiency.

Influence on the ability to drive vehicles and mechanisms

Afalaza drug does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Overdose

In case of an accidental overdose, dyspeptic symptoms are possible due to the fillers included in the drug.

Drug interactions

Cases of incompatibility with other drugs have not been registered to date.